Oppenheimer Asset Management Inc. Raises Stock Holdings in Humana Inc. (NYSE:HUM)

Oppenheimer Asset Management Inc. raised its holdings in Humana Inc. (NYSE:HUM - Free Report) by 197.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,835 shares of the insurance provider's stock after buying an additional 6,533 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Humana were worth $2,602,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Dodge & Cox raised its stake in Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after buying an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after acquiring an additional 1,751,857 shares during the period. Norges Bank purchased a new position in shares of Humana during the 4th quarter worth approximately $416,202,000. Pzena Investment Management LLC raised its position in shares of Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after acquiring an additional 1,103,132 shares in the last quarter. Finally, Boston Partners lifted its stake in shares of Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock valued at $279,236,000 after purchasing an additional 893,637 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of HUM traded up $2.42 during trading hours on Monday, hitting $244.30. The stock had a trading volume of 1,231,851 shares, compared to its average volume of 1,804,980. The firm has a market capitalization of $29.48 billion, a PE ratio of 17.28, a PEG ratio of 1.82 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. Humana Inc. has a 12 month low of $212.45 and a 12 month high of $406.46. The stock has a fifty day moving average price of $241.90 and a 200 day moving average price of $259.00.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The business had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. During the same period last year, the firm posted $7.23 earnings per share. The business's revenue for the quarter was up 8.4% on a year-over-year basis. Analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.45%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio is presently 25.04%.

Analyst Ratings Changes

A number of equities analysts have issued reports on HUM shares. Oppenheimer increased their price objective on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a report on Thursday, May 1st. Bank of America lowered their price target on shares of Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research report on Tuesday, June 17th. Wall Street Zen raised shares of Humana from a "hold" rating to a "buy" rating in a research note on Friday. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a research note on Thursday, May 1st. Finally, Barclays set a $268.00 price objective on Humana and gave the company an "equal weight" rating in a research note on Thursday, June 12th. Sixteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, Humana has a consensus rating of "Hold" and an average target price of $280.76.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.